Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Lymphoma, also known as malignant lymphoma, is a general term for a group of malignant tumors originating from the lymphopoietic system. It is one of the most common tumors in China. In 2020, there were 544,352 new cases of non-Hodgkin lymphoma (NHL) worldwide, ranking 13th among all new cases of malignancies.

Illumina will bring its genomics startup incubator to the UK next year.

The Parkinson's Foundation and Fulgent Genetics announced recently that they have begun a collaboration on a new genetic testing initiative for Parkinson's disease patients. The group said that the initiative, called PD GENEration: Mapping t

Abbott recently said that its Diagnostics business revenues grew 2 percent year over year in the second quarter, while its total revenues were up 3 percent.

PathogenDx has entered into a strategic partnership with Nationwide Laboratory Services for fungal testing of dermatology and podiatry samples.

Danaher recently reported a 4 percent year-over-year increase in its second quarter revenues, which included a 6 percent rise in life sciences segment revenues and a rise of almost 5 percent in its diagnostics segment.

Life sciences and health data startup Seer announced recently that it has raised $17.5 million in a series C financing round.

Danaher recently announced that the group will establish an independent company, ENVISTA HOLDINGS CORPORATION (referred to as Envista), and will make an initial public offering in the second half of 2019.

Roche today reported flat half-year revenues for its Diagnostics division. At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business as well as to overall growth in the second quarter

Freenome announced today that it has closed a $160 million Series B financing round, which it will use to further develop its early cancer detection blood test.

Thermo Fisher Scientific, the world leader in serving science, recently announced that it will be investing more than $50m (£39.8m) in its global bioproduction capabilities to provide additional capacity for manufacturing single-use bioproc